On the other hand, a SCCA1 score of ≥2 [43] identifies a subgroup of patients with stage IV NSCLC who have a poor survival when treated with PtC, similar to that estimated of untreated or chemorefractory stage IV NSCLC, indicating SCCA1 as a useful biomarker that identifies a highly resistant subgroup for whom PtC should be avoided [43]. Here, SERPINB3 is linked to non-small cell lung carcinoma.